Stephane Bardet

Stephane Bardet

Caen, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 69 publications

ENDOCAN TUTHYREF network consensus recommendations: Anaplastic thyroid cancer.

ENDOCAN TUTHYREF network consensus recommendations: Anaplastic thyroid cancer.

Journal: Annales d'endocrinologie

Published: April 06, 2025

ENDOCAN TUTHYREF network consensus recommendations: Refractory follicular-derived thyroid cancer.

ENDOCAN TUTHYREF network consensus recommendations: Refractory follicular-derived thyroid cancer.

Journal: Annales d'endocrinologie

Published: April 06, 2025

NSD3::NUTM1 fusion evidenced on RNA sequencing in poorly differentiated thyroid cancer: a report of two cases.

NSD3::NUTM1 fusion evidenced on RNA sequencing in poorly differentiated thyroid cancer: a report of two cases.

Journal: European thyroid journal

Published: March 28, 2025

False-Positive Radioiodine Uptake Related to Posttraumatic Scab Demonstrated by SPECT/CT in a Patient With Differentiated Thyroid Cancer.

False-Positive Radioiodine Uptake Related to Posttraumatic Scab Demonstrated by SPECT/CT in a Patient With Differentiated Thyroid Cancer.

Journal: Clinical nuclear medicine

Published: November 12, 2024

Title Not Found

Title Not Found

Journal: Bulletin du cancer

Published: November 06, 2024

F18-Choline PET/CT or MIBI SPECT/CT in the Surgical Management of Primary Hyperparathyroidism: A Diagnostic Randomized Clinical Trial.

F18-Choline PET/CT or MIBI SPECT/CT in the Surgical Management of Primary Hyperparathyroidism: A Diagnostic Randomized Clinical Trial.

Journal: JAMA otolaryngology-- head & neck surgery

Published: June 20, 2024

Thyroidectomy without radioiodine in patients with low-risk thyroid cancer: 5 years of follow-up of the prospective randomised ESTIMABL2 trial.

Thyroidectomy without radioiodine in patients with low-risk thyroid cancer: 5 years of follow-up of the prospective randomised ESTIMABL2 trial.

Journal: The lancet. Diabetes & endocrinology

Published: June 14, 2024

Selpercatinib - First-line in advanced progressive RET-mutant medullary thyroid cancer

Selpercatinib - First-line in advanced progressive RET-mutant medullary thyroid cancer

Journal: Bulletin du cancer

Published: May 20, 2024

18F-Fluorodeoxyglucose PET-CT evaluation after one course of neoadjuvant therapy fails to predict pCR in HER2 + BC patients: a prospective and multicentric French study.

18F-Fluorodeoxyglucose PET-CT evaluation after one course of neoadjuvant therapy fails to predict pCR in HER2 + BC patients: a prospective and multicentric French study.

Journal: Breast cancer research : BCR

Published: May 03, 2024

Safety and efficacy of nintedanib as second-line therapy for patients with differentiated or medullary thyroid cancer progressing after first-line therapy. A randomized phase II study of the EORTC Endocrine Task Force (protocol 1209-EnTF).

Safety and efficacy of nintedanib as second-line therapy for patients with differentiated or medullary thyroid cancer progressing after first-line therapy. A randomized phase II study of the EORTC Endocrine Task Force (protocol 1209-EnTF).

Journal: Frontiers in endocrinology

Published: March 19, 2024

Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer.

Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer.

Journal: The New England journal of medicine

Published: October 23, 2023

Artificial intelligence solution to accelerate the acquisition of MRI images: Impact on the therapeutic care in oncology in radiology and radiotherapy departments.

Artificial intelligence solution to accelerate the acquisition of MRI images: Impact on the therapeutic care in oncology in radiology and radiotherapy departments.

Journal: Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique

Published: October 19, 2023

Showing 1-12 of 69

Last Updated: 09/26/2026